Manufacturing, Combination Drugs

Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.

Financial expectations for Baxter’s biopharma solutions arm will drop 10% as the result of a client’s decision to move its manufacturing in house.

Novasep's new antibody drug conjugate facility at its site in Le Mans, France will be commissioned in 2016.

As ADCs move through the drug-development process, different analytical methods are often required.

New toxicology study demonstrates decreased mortality and better tolerability of ADC generated with Smartag platform versus conventional technology.

ThioBridge linker technology to attach different payloads to a range of antibodies

Phase I/II study to evaluate treatment of patients with melanoma using Pfizer’s palbociclib and GSK’s trametinib.

Roche plans multimillion biologic manufacturing expansions in California, Switzerland, and Germany.

The first part of CPhI's Annual Expert Industry Report examines ADCs, single-use technology, and regulatory failure.

Seattle Genetics could potentially receive approximately $500 million in fees, milestones and royalties.

While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.

Catalent Pharma Solutions has acquired a license to market Redwood Bioscience 's proprietary SMARTag precision protein-chemical engineering technology.

Astellas and Ambrx have entered into a collaboration to discover and develop novel antibody drug conjugates (ADCs) for an undisclosed number of targets in oncology. ADCs enable targeted delivery of drugs to the target tissue.

Industry experts discuss the benefits and challenges of self-administration of injectable therapies.

How an electronics engineer led the first Indian company to carry out indigenous development of a recombinant vaccine.